19-norepietiocholanolone | 64044-10-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 19-norepietiocholanolone
• 英文别名: 3β-hydroxy-19-nor-5β-androstane-17-one；3β-hydroxy-5β-estrane-17-one；19-Noretiocholan-3b-ol-17-one；(3S,5R,8R,9R,10S,13S,14S)-3-hydroxy-13-methyl-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-one
• CAS: 64044-10-6
• 化学式: C₁₈H₂₈O₂
• 分子量: 276.419
• InChiKey: UOUIARGWRPHDBX-MTYWFVNZSA-N

物化性质

• 熔点：
  165.0-166.5 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  412.9±45.0 °C(Predicted)
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  19-norepietiocholanolone 在 吡啶 、 samarium diiodide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.0h， 生成 (3α,5β,17β)-3-hydroxyandrostane-17-carbonitrile
  参考文献：
  名称：

  Neurosteroid Analogues. 4. The Effect of Methyl Substitution at the C-5 and C-10 Positions of Neurosteroids on Electrophysiological Activity at GABA_A Receptors

  摘要：

  A series of analogues of the neuroactive steroids 3 alpha-hydroxy-5 alpha-pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one were studied to elucidate the mode of binding of 5 alpha- and 5 beta-reduced steroids to steroid binding sites on GABA(A) receptors. Analogues which were either 3 alpha-hydroxy-20-ketosteroids or 3 alpha-hydroxysteroid-17 beta-carbonitriles and which contained various methyl group substitution patterns at C-5 and C-10 were prepared. Evaluations utilized whole-cell patch clamp electrophysiological methods carried out on cultured rat hippocampal neurons, and the results obtained with the rigid 17 beta-carbonitrile analogs were analyzed using molecular modeling methods. The molecular modeling results provide a rationale for the observation that the configuration of the hydroxyl group at C-3 is a greater determinant of anesthetic potency than the configuration of the A,B ring fusion at C-5. The electrophysiological results identify steric restrictions for the space that can be occupied in 5 alpha- and 5 beta-reduced steriod modulators of GABA(A) receptors in the regions of space proximate to the steroid C-5, C-10, and possibly C-4 positions. This information is useful for the development of nonsteroidal analogues that can modulate GABA(A) receptors via interactions at steroid binding sites.

  DOI：

  10.1021/jm960304p
• 作为产物：
  描述：

  诺龙 在 palladium on activated charcoal chromium(VI) oxide 、 氢氧化钾 、 硫酸 、 氢气 、 potassium tri-sec-butyl-borohydride 作用下， 以 四氢呋喃 为溶剂， 反应 6.5h， 生成 19-norepietiocholanolone
  参考文献：
  名称：

  Neurosteroid Analogues. 4. The Effect of Methyl Substitution at the C-5 and C-10 Positions of Neurosteroids on Electrophysiological Activity at GABA_A Receptors

  摘要：

  A series of analogues of the neuroactive steroids 3 alpha-hydroxy-5 alpha-pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one were studied to elucidate the mode of binding of 5 alpha- and 5 beta-reduced steroids to steroid binding sites on GABA(A) receptors. Analogues which were either 3 alpha-hydroxy-20-ketosteroids or 3 alpha-hydroxysteroid-17 beta-carbonitriles and which contained various methyl group substitution patterns at C-5 and C-10 were prepared. Evaluations utilized whole-cell patch clamp electrophysiological methods carried out on cultured rat hippocampal neurons, and the results obtained with the rigid 17 beta-carbonitrile analogs were analyzed using molecular modeling methods. The molecular modeling results provide a rationale for the observation that the configuration of the hydroxyl group at C-3 is a greater determinant of anesthetic potency than the configuration of the A,B ring fusion at C-5. The electrophysiological results identify steric restrictions for the space that can be occupied in 5 alpha- and 5 beta-reduced steriod modulators of GABA(A) receptors in the regions of space proximate to the steroid C-5, C-10, and possibly C-4 positions. This information is useful for the development of nonsteroidal analogues that can modulate GABA(A) receptors via interactions at steroid binding sites.

  DOI：

  10.1021/jm960304p

文献信息

• 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20030162701A1

  公开（公告）日：2003-08-28

  A 19-norbufalin derivative compound of formula (I) and isomers pharmaceutically acceptable salts thereof. Compounds of formula (I) are Na + ,K + -ATPase inhibitors and can be used in the treatment of cardiac and/or vascular malfunction, renal malfunction, as digoxin antagonists, for treatment of CNS disorders and for the treatment of malignant and proliferative cell diseases.

  公式(I)的19-去甲波非林衍生物化合物及其药用可接受盐的异构体。 公式(I)的化合物是Na+，K+-ATPase抑制剂，可用于治疗心脏和/或血管功能障碍，肾功能障碍，作为地高辛拮抗剂，用于治疗中枢神经系统疾病以及治疗恶性和增生性细胞疾病。
• Hydroxysteroid Dehydrogenase-Catalyzed Highly Regio-, Chemo-, and Enantioselective Hydrogenation of 3-Keto in Steroids
  作者：Chunling Zeng、Shitang Xu、Jie Shen、Saijie Zhao、Xinhua Xu、Lifen Peng

  DOI：10.1021/acs.orglett.3c03557

  日期：2024.1.12

  A highly selective hydrogenation of 3-keto in steroids to 3-hydroxyl steroids catalyzed by hydroxysteroid dehydrogenases (HSDHs) was demonstrated. The Ct3α-HSDH-catalyzed hydrogenation generated 3α-hydroxyl steroids as the main enantiopure isomers in high yields, while the Ss3β-HSDH catalytic system afforded 3β-hydroxyl steroids in excellent yields. In both catalytic systems, the hydrogenation proceeded

  证明了在羟基类固醇脱氢酶 (HSDH) 的催化下，类固醇中的 3-酮基可以高度选择性地氢化为 3-羟基类固醇。 Ct3α-HSDH催化的氢化反应以高产率产生了作为主要对映体纯异构体的3α-羟基类固醇，而Ss3β-HSDH催化体系则以优异的产率产生了3β-羟基类固醇。在两种催化体系中，氢化反应在 3-酮基上进行区域选择性，7-、11-、17-和 20-酮基几乎未反应，并且在 C=C 键和酯基未受攻击的情况下进行化学选择性氢化。我们的HSDH促进的氢化反应具有区域选择性、化学选择性和对映选择性高、收率好、条件温和、底物范围广、适合克级合成等优点。值得注意的是，通过我们的氢化方法，可以轻松、高产地获得脱氢表雄酮、布烯醇酮和阿法沙酮等生物活性分子。
• STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：EP3750908A1

  公开（公告）日：2020-12-16

  The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.

  本发明涉及类固醇衍生物调节剂、其制备方法及其用途。具体而言，本发明涉及一种式（I）化合物、其制备方法、含有该化合物的药物组合物及其作为 GABA A 受体调节剂用于治疗抑郁症、抽搐、帕金森病和神经系统疾病的用途，其中式（I）的取代基如描述中所定义。
• [EN] STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF<br/>[FR] RÉGULATEUR DE DÉRIVÉ DE STÉROÏDE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种甾族类衍生物调节剂及其制备方法和应用
  申请人：JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD

  公开号：WO2019154257A1

  公开（公告）日：2019-08-15

  本发明涉及一种甾族类衍生物调节剂及其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为GABAA受体调节剂在治疗抑郁症、惊厥、帕金森和神经系统疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。
• An Improved Synthesis of 18-Nor-17-ketosteroids and Application of the Method for the Preparation of (3β,5β,13α)- and (3β,5β,13β)-3-Hydroxygonan-17-one
  作者：Mingcheng Han、Douglas F. Covey

  DOI：10.1021/jo9611430

  日期：1996.1.1